The NICE-PAD II Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 250 participants.

Also called NCT07782671

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07782671
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07782671. Randomized; quadruple masking; primary purpose treatment. Start 2027-02 (anticipated); primary completion 2030-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The NICE-PAD II Trial
Acronym
NICE
Condition
Peripheral Artery Disease (PAD)
Intervention (Drug)
Nicotinamide Riboside (NR)
Intervention (Drug)
Placebo
Lead sponsor
Northwestern University (class: other)
Collaborator
National Institute on Aging (NIA) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct07782671
Content hash
43604581d9354a08644447bc203d8e6d5dc9258b3aadf4c789e06cbc53b6bb60